This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Biogen Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
by Ekta Bagri
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
by Zacks Equity Research
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.
Is the Future Bleak for SAVA Stock Following Another Setback?
by Zacks Equity Research
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
by Zacks Equity Research
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
by Zacks Equity Research
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
by Zacks Equity Research
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
by Zacks Equity Research
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
by Zacks Equity Research
Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
by Zacks Equity Research
The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
by Zacks Equity Research
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
by Zacks Equity Research
IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
by Zacks Equity Research
GILD and BIIB are in the spotlight this week on fourth-quarter earnings release and outlook for 2025.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
by Zacks Equity Research
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
by Zacks Equity Research
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen (BIIB) delivered earnings and revenue surprises of 0.58% and 1.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.